India's Lupin is banking on the fast-growing domestic diabetes market and said it has signed a deal with Germany's Boehringer Ingelheim to sell linagliptin, a blood glucose (dipeptidyl peptidase-4) inhibitor for Type 2 diabetes, in India, according to a story from Livemint. Lupin will market and sell the drug under a separate brand name and Boehringer will still use its brand names, Trajenta and TrajentaDuo treatments. The Indian diabetes drug market is growing at nearly 20% a year, Livemint reported. In 2011, Lupin also signed an agreement with Eli Lilly ($LLY) to promote and distribute Lilly's antidiabetic drugs in India and Nepal. Lupin's antidiabetic portfolio contributes 15% to India formulations sales, according to the story. The company has a market share of 6.44% in the overall diabetes drug market. "I believe our entry into the high growth DPP-4 inhibitor market with the launch of Ondero and Ondero Met will not only strengthen our diabetes portfolio but also help us consolidate our position as a market leader and the fastest-growing player in the Top 5 in the anti-diabetes segment," said Shakti Chakraborty, group president for India formulations at Lupin, Livemint reported. Story